News and Press Releases

Prosarix's de novo design application, ProtoBuild™, used to design novel PPARα/γ dual agonists

Cambridge, UK, February 3rd 2011 — As part of a collaborative project with Imperial College Genetics Therapy Centre, the University of Bergen and Haukeland University Hospital, Prosarix utlised its proprietary de novo design software, ProtoBuiild™ to design a number of novel PPAR α/γ dual agonists. A paper describing the in silico design, synthesis and in vitro characterisation of a novel series of 2,5-disubstituted indole compounds has now been published.

This demonstrates a new de novo design methodology implemented by the ProtoBuild™ program and its ability to rapidly produce novel modulators for a well characterized drug target.

Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD

Bhurruth-Alcor Y1, Røst T2, Jorgensen MR1, Kontogiorgis C1, Skorve J2, Cooper RG4, Sheridan JM4, Hamilton WDO4, Heal JR4, Berge RK3 and Miller AD1

1 Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building,
  Armstrong Road, Imperial College London, London, UK, SW7 2AZ
2 Institute of Medicine, University of Bergen, N-5021, Bergen, Norway
3 Department of Heart Disease, Haukeland University Hospital, N-5021, Bergen, Norway
4 Prosarix Ltd, Newton Hall, Cambridge, CB22 7ZE, United Kingdom.

Organic & Biomolecular Chemistry (2011) 9:1169-1188


©Prosarix 2007-2020

℅ RxCelerate Ltd, Moneta B280, Babraham Research Park, Cambridge, CB22 3AT ¦ +44 (0)1223 839557 ¦ ¦ legal